Tiziana Life Sciences (Nasdaq: TLSA) to highlight foralumab at forum
Rhea-AI Filing Summary
Tiziana Life Sciences Ltd filed a Form 6-K to share that CEO Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum in San Francisco at 2:00 PM PT on January 11, 2026, during J.P. Morgan Healthcare Conference Week. Senior management will also attend for one-on-one meetings with investors, partners, and other stakeholders.
The presentation will focus on Tiziana’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions. The company reports that 14 patients with non-active secondary progressive multiple sclerosis in an expanded access program showed improvement or disease stability within 6 months, and intranasal foralumab is also being studied in a Phase 2a randomized, double-blind, placebo-controlled trial.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January 2026
Commission File Number: 001-38723
Tiziana Life Sciences LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On January 9, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines’ Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TIZIANA LIFE SCIENCES LTD | |||
| Date: January 9, 2026 | By: | /s/ Keeren Shah | |
| Name: | Keeren Shah | ||
| Title: | Chief Financial Officer | ||
2
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Tiziana Life Sciences LTD Press Release, dated January 9, 2026 |
3
Exhibit 99.1
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
BOSTON, MA, January 9, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum, organized by Sachs Associates. The presentation is scheduled for 2:00 PM PT on January 11, 2026, at the Marines’ Memorial Club in San Francisco, California, during J.P. Morgan Healthcare Conference Week.
Members of Tiziana’s senior management team will also attend the forum and be available for one-on-one meetings with investors, partners, and other stakeholders.
The 9th Annual Neuroscience Innovation Forum is a premier industry event featuring keynotes, panel discussions, and company presentations focused on advances in therapeutics, neurotechnology, and diagnostics for neurological disorders. Tiziana’s presentation will highlight the Company’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions.
“We are excited to participate in this prestigious forum alongside leading innovators in neuroscience,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This event provides an important platform to share updates on our clinical progress with intranasal foralumab and to engage with potential partners as we advance therapies for patients suffering from devastating diseases such as non-active secondary progressive multiple sclerosis and other neuroinflammatory conditions.”
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biologic candidate that has been shown to stimulate T regulatory cells when dosed intranasally. Currently, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor
Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
| [1] | https://www.pnas.org/doi/10.1073/pnas.2220272120 |
| [2] | https://www.pnas.org/doi/10.1073/pnas.2309221120 |
FAQ
What did Tiziana Life Sciences (TLSA) announce in this Form 6-K?
Tiziana Life Sciences announced that CEO Ivor Elrifi will deliver a corporate presentation at the 9th Annual Neuroscience Innovation Forum in San Francisco on January 11, 2026, during J.P. Morgan Healthcare Conference Week.
What is Tiziana Life Sciences’ lead drug candidate intranasal foralumab?
Intranasal foralumab is Tiziana’s lead candidate, described as a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce microglial activation in neurodegenerative conditions.
What clinical experience with intranasal foralumab does Tiziana Life Sciences (TLSA) describe?
Tiziana reports that 14 patients with non-active secondary progressive multiple sclerosis in an open-label, intermediate-sized expanded access program showed either improvement or stability of disease within 6 months of intranasal foralumab treatment.
What ongoing clinical trial is evaluating intranasal foralumab?
Intranasal foralumab is being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis, identified as NCT06292923.
How does Tiziana Life Sciences (TLSA) describe the uniqueness of foralumab?
Tiziana states that foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, and that intranasal delivery may offer a novel immunomodulatory approach for neuroinflammatory and neurodegenerative diseases.
What is the focus of the 9th Annual Neuroscience Innovation Forum that Tiziana will attend?
The forum is described as a premier industry event featuring keynotes, panels, and company presentations on advances in therapeutics, neurotechnology, and diagnostics for neurological disorders, where Tiziana will highlight its intranasal foralumab program.
What stage is Tiziana Life Sciences (TLSA) as a company?
Tiziana describes itself as a clinical-stage biopharmaceutical company developing therapies that use transformational drug delivery technologies, including its nasal approach to immunotherapy.
